Day: November 10, 2021

LOS ANGELES, Nov. 10, 2021 (GLOBE NEWSWIRE) — Crescent Capital BDC, Inc. (“Crescent BDC” or “Company”) (NASDAQ: CCAP) today reported net investment income of $12.7 million, or $0.45 per share, and Adjusted Net Investment Income of $13.5 million, or $0.48 per share,1 for the quarter ended September 30, 2021. Reported net asset value per share was $21.16 at September 30, 2021 as compared to $20.98 at June 30, 2021. The Company announced that its Board of Directors declared the following cash dividends on November 5, 2021:Cash Dividend Type    Record Date    Payment Date    Amount Per ShareRegular    December 31, 2021    January 17, 2022    $ 0.41Special    December 3, 2021    December 15, 2021    $ 0.05Special    March 4, 2022    March 15, 2022    $ 0.05Special    June 3, 2022    June 15, 2022    $ 0.05Special    September 2, 2022    September 15, 2022    $ 0.05               Selected...

Third quarter total revenues of $201.1 million, representing 64.2% of year-over-year growth, which was entirely organic. GAAP net income margin of 5.8%, including non-cash stock-based compensation expense of $19.2 million. Adjusted EBITDA margin of 23.9%, non-GAAP adjusted net income margin of 16.3%. Full year 2021 outlook for revenues between $747 and $751 million, representing growth of approximately 56.7% at the midpoint, and Adjusted EBITDA margins of between 24.0% and 24.2%.NEW BRAUNFELS, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) — TaskUs, Inc. (Nasdaq: TASK), a leading outsourcing provider for high growth companies, today announced its results for the third quarter of 2021, ended September 30, 2021. “We had a tremendous quarter in signings, revenue, profit, client retention and employee satisfaction,” said Co-Founder and CEO,...

Third quarter 2021 net sales were $49.2 million, a decrease of 6.8% (or 7.1% on a constant currency basis) versus the prior year period due to Northern Hemisphere harvest timing and extreme weather events; year-to-date net sales increased 4.1% versus the prior year period. Diversification revenue (i.e. excluding sales of SmartFresh TM for apples) grew 14.6% for the trailing twelve month period ended September 30, 2021 versus the twelve months ended September 30, 2020, and represented 41.3% of consolidated revenues during this period. Net income of $0.8 million for the third quarter of 2021, as compared to net loss of $29.7 million for the third quarter of 2020. For the nine months ended September 30, 2021 net loss was $8.3 million, compared to net loss of $50.3 million in the prior year period. Adjusted EBITDA1 of $20.5 million for the...

Over 100 clinical sites now activated in RESPONSE Phase 3 registration study of seladelpar for patients with primary biliary cholangitis (PBC) Additional data from prior studies of seladelpar in patients with PBC to be featured at The Liver Meeting® November 12-15, 2021 held by the American Association for the Study of Liver Diseases (AASLD) CymaBay to host Post-AASLD KOL call on November 15 at 4:30pm ET Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the third quarter ended September 30, 2021. Sujal Shah, President and CEO of CymaBay, stated,...

Added important patents further protecting the company’s therapeutic delivery technologies Added strong biotherapeutics capabilities to management team and board of directors Implemented cost-cutting measures expected to result in approximately $145 million in cost savings on an annual basis1 Management will host conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021. During the third quarter, Progenity added four patents related to its ingestible device and method technologies designed for delivery of therapeutics via the gastrointestinal (GI) tract, further strengthening one of the most...

Gevo to Host Conference Call Today at 4:30 p.m. EST/2:30 p.m. MST ENGLEWOOD, Colo., Nov. 10, 2021 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) today announced financial results for the third quarter of 2021 and recent corporate highlights. Recent Corporate HighlightsOn October 25, 2021, Gevo announced that it signed a memorandum of understanding (“MoU”) with Archer-Daniels-Midland Company (“ADM”) to support the production of sustainable aviation fuel (“SAF”) and other low carbon-footprint hydrocarbon fuels. The MoU contemplates the production of both ethanol and isobutanol that would then be transformed into renewable low carbon-footprint hydrocarbons using Gevo’s processing technology and capabilities.On October 12, 2021, Gevo announced that it entered into an agreement with Axens North America, Inc. (“Axens”) that establishes...

PITTSBURGH, Nov. 10, 2021 (GLOBE NEWSWIRE) — Duolingo, Inc. (NASDAQ: DUOL), the world’s leading mobile language platform, today announced financial results for the quarter ended September 30, 2021. “Our performance during the third quarter was exceptional. We achieved record bookings and a record number of paid subscribers, with monthly and daily users also reaching all-time highs,” said Luis von Ahn, Co-Founder and CEO of Duolingo. “I’m very proud that we continue to grow rapidly, even on top of last year’s extraordinary performance, furthering our mission to develop the best education in the world and make it universally available.” Third Quarter 2021 Operational HighlightsTotal bookings were $73.1 million, an increase of 57% from the prior year quarter; Subscription bookings were $55.4 million, an...

HORSHAM, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the quarter ended September 30, 2021. Third Quarter 2021 HighlightsTotal revenue was $7.7 million, an increase of 37.4% as compared to the third quarter of 2020Recurring revenue was $5.7 million, a 48.9% increase over the third quarter of 2020 Gross domestic recurring billings were $5.8 million, a 23.5% increase over the third quarter 2020 (See Reconciliation of Non-GAAP measures below)Total gross margins were 69.7%, a 12.2% increase over third quarter 2020 Entered into a credit and security agreement with MidCap Financial Trust, providing STRATA...

Increases Full Year 2021 GuidanceThird quarter total revenue of $91.8 million, up 36% YoY GAAP net loss of $24.8 million, compared to GAAP net income of $3.2 million in third quarter 2020 Adjusted EBITDA loss of $12.4 million, compared to Adjusted EBITDA of $3.3 million in third quarter 2020 Raises 2021 revenue guidance to a range of $341 to $344 million; YoY growth of 64% to 65%BUFFALO, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) — ACV (Nasdaq: ACVA), the leading online automotive marketplace for dealers, today reported results for its third quarter ended September 30, 2021. “We were very pleased with our solid results in the third quarter, which once again exceeded expectations, despite ongoing supply challenges impacting the automotive industry. Our growth is driven by continued market share gains, strong adoption of ACV’s value-added...